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Hmga2 is dispensable for 
pancreatic cancer development, 
metastasis, and therapy resistance
Shin-Heng Chiou1, Madeleine Dorsch2, Eva Kusch2, Santiago Naranjo1, Margaret M. Kozak3, 
Albert C. Koong3,4, Monte M. Winslow1,5,6 & Barbara M. Grüner  2,7
Expression of the chromatin-associated protein HMGA2 correlates with progression, metastasis and 
therapy resistance in pancreatic ductal adenocarcinoma (PDAC). Hmga2 has also been identified as 
a marker of a transient subpopulation of PDAC cells that has increased metastatic ability. Here, we 
characterize the requirement for Hmga2 during growth, dissemination, and metastasis of PDAC in vivo 
using conditional inactivation of Hmga2 in well-established autochthonous mouse models of PDAC. 
Overall survival, primary tumour burden, presence of disseminated tumour cells in the peritoneal cavity 
or circulating tumour cells in the blood, and presence and number of metastases were not significantly 
different between mice with Hmga2-wildtype or Hmga2-deficient tumours. Treatment of mice with 
Hmga2-wildtype and Hmga2-deficient tumours with gemcitabine did not uncover a significant impact 
of Hmga2-deficiency on gemcitabine sensitivity. Hmga1 and Hmga2 overlap in their expression in both 
human and murine PDAC, however knockdown of Hmga1 in Hmga2-deficient cancer cells also did not 
decrease metastatic ability. Thus, Hmga2 remains a prognostic marker which identifies a metastatic 
cancer cell state in primary PDAC, however Hmga2 has limited if any direct functional impact on PDAC 
progression and therapy resistance.
Pancreatic ductal adenocarcinoma (PDAC) is among the most fatal of all malignancies1. Due to its high rate of 
metastatic spread and poor response to therapy the five-year survival rate for PDAC patients remains below ten 
percent and PDAC is projected to be the second most common cause of cancer deaths by 20302. While PDAC is 
well characterized genomically,3,4 the mechanisms that enable cancer cells to leave their primary site and form 
distant metastases remain largely unknown5–10. The most common driver mutations in human PDAC are onco-
genic mutations in KRAS and loss of the tumour suppressors CDKN2A, SMAD4, and TP53. These alterations are 
present in both primary tumours and metastases and additional genomic alterations specific to metastases have 
not been identified6,11. Several recent studies have suggested that PDAC metastasis is driven by epigenetic alter-
ations, metabolic changes, and microenvironment-induced gene expression alterations10,12–15. Due to its highly 
metastatic nature, most PDAC patients are diagnosed at an advanced disease stage with local or distant metastasis 
and are therefore not candidates for potentially curative surgery. Thus, the majority of patients are treated with 
chemotherapy. However, chemotherapeutic regimens and targeted therapies are largely ineffective, and tumours 
that do respond rapidly develop resistance12,15–17.
Genetically engineered mouse models of PDAC recapitulate many aspects of the human disease. 
Pancreas-specific expression of oncogenic KrasG12D and Cre/loxP-based inactivation of the tumour suppressors 
that are frequently inactivated in human PDAC results in the development of murine PDAC that is histologically 
and molecularly similar to the human disease18,19. These models recapitulate the entire course of the disease, from 
the development of preneoplastic lesions to invasive carcinomas and the development of widespread metastatic 
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disease19–22. Importantly, these models also allow the impact of additional genetic alterations to be investigated 
during the initiation and progression of pancreatic cancer, as well as response to therapy in vivo23–25.
HMGA2 (high mobility group A2) is a chromatin-associated DNA-binding protein that is expressed in 
embryonic stem cells and during development, but is absent from most adult somatic cells26,27. Interestingly, 
HMGA2 is re-expressed in many human malignancies, including PDAC, where high expression correlates with 
lymph node metastasis, increased tumour grade, and reduced patient survival28–34. HMGA2 has been shown to 
interact with histones and alter DNA topology through binding to the minor groove of DNA26. Due to its high 
expression in multiple cancer types at advanced stages as well as in metastases, it has been suggested that HMGA2 
functions to drive metastatic ability27,28,30,34–39. Recently, using genetically engineered mouse models, we defined 
a transient, Hmga2-positive subpopulation of PDAC cells that has increased metastatic ability13. However, it 
remains unclear whether Hmga2 is a functionally important driver of the pro-metastatic properties of these cells 
or only a marker of this state.
In this study, we directly investigated the importance of Hmga2 during PDAC development, metastasis, and 
therapy response in vivo. We conditionally inactivated Hmga2 in well-established autochthonous PDAC mod-
els and found no effect of Hmga2 inactivation on tumour initiation, progression, or metastasis. The absence of 
Hmga2 also did not dramatically alter the response of autochthonous PDAC to gemcitabine treatment.
Results
Hmga2 deficiency does not impact the survival of PDAC bearing mice. To investigate the role of 
Hmga2 in PDAC, we first confirmed Hmga2 expression in the carcinoma stage of pancreatic cancer tissue iso-
lated from the well-established autochthonous KrasLSL-G12D/+;p53LSL-R172H/+;Rosa26LSL-tdTomato/+;Pdx1-Cre (KP172CT) 
mouse model of PDAC (Fig. 1a, Supplementary Fig. S1a). Recently, we uncovered Hmga2 as a marker of a tran-
sient subpopulation of pancreatic cancer cells with increased metastatic ability in KP172CT mice13. To mark 
Hmga2positive cells within autochthonous PDAC, we utilized a conditional Hmga2 allele that converts from the 
unrecombined Hmga2CK conformation to a null-allele/GFP-knock-in reporter (Hmga2GFP) upon Cre-mediated 
inversion of a splice-acceptor-GFP-splice-donor cassette13,40.
To initially investigate whether pancreas-specific inactivation of Hmga2 would grossly alter pancreatic devel-
opment and size, we generated Hmga2CK/CK;Pdx1-Cre mice. These mice were born at expected Mendelian ratios 
and developed normally. Pancreata from 4-week and 11-week-old mice showed no signs of malformation of the 
exocrine or endocrine compartments, as assessed both by organ weight and histology (Supplementary Fig. S1b,c).
To investigate the role of Hmga2 during pancreatic tumourigenesis, we incorporated the Hmga2CK allele and 
a Rosa26LSL-tdTomato/+ reporter allele into the KrasLSL-G12D/+;p53LSL-R172H/+;Pdx1-Cre (KP172C) background (Fig. 1a). 
We generated KP172CT;Hmga2CK/+ and KP172CT;Hmga2CK/CK tumour-bearing mice. Immunohistochemistry 
for Hmga2, tdTomato, and the GFP fusion protein confirmed that Hmga2 expression in neoplastic cells in 
KP172CT;Hmga2CK/+ mice overlaps with GFP expression and that Hmga2 protein is absent from all tumours 
in KP172CT;Hmga2CK/CK mice (Fig. 1b). To analyse whether Hmga2 deficiency impacts the development and 
progression of PDAC, we generated cohorts of KP172CT;Hmga2CK/CK and KP172CT;Hmga2+/+ mice. Gross 
cancer-associated phenotypes were comparable, with mice showing similar cachexic symptoms as well as the 
development of ascites and jaundice in some mice (data not shown). Kaplan-Meier analysis showed no significant 
survival difference between KP172CT;Hmga2CK/CK and KP172CT;Hmga2+/+ mice. There was even a trend towards 
slightly shorter survival of KP172CT;Hmga2CK/CK mice (Fig. 1c).
To further investigate the impact of Hmga2 deficiency on PDAC growth, we employed a second mouse model 
of PDAC, where instead of expression of a dominant negative p53 allele (p53LSL-R172H) we incorporated a p53floxed 
allele to enable conditional heterozygous deletion of p53 (p53flox/+, Fig. 1a right panel). We generated KrasLSL-G12D/+; 
p53flox/+;Rosa26LSL-tdTomato/+;Pdx1-Cre;Hmga2+/+ (KPHetCT;Hmga2+/+) and KPHetCT;Hmga2CK/CK mice and assessed 
overall survival. Consistent with our data from the KP172CT model, Hmga2-deficiency did not significantly alter 
overall survival and gross disease-associated phenotypes in both groups were comparable (Fig. 1d and data not 
shown). Collectively, these data suggest that Hmga2 inactivation has limited, if any, effect on overall pancreatic 
tumour growth.
Hmga2 deficiency does not change PDAC phenotypes. To investigate the impact of Hmga2 defi-
ciency on pancreatic cancer phenotypes in KP172CT and KPHetCT mice, we assessed tumour histology. At the 
time of analysis, most KP172CT;Hmga2+/+ and KP172CT;Hmga2CK/CK animals had developed pancreatic ade-
nocarcinoma (Fig. 2a,c). In these mice, tumours were of similar size and were characterized by the presence 
of mPanINs and glandular structures accompanied by an extensive desmoplastic reaction (data not shown). 
Regardless of genotype, tumours had both well- and poorly-differentiated areas which is typical for tumours in 
this model18. Detailed histological analyses did not uncover any differences in the histological features of mice 
with Hmga2-deficient or Hmga2-wildtype tumours. Similarly, KPHetCT;Hmga2+/+ and KPHetCT;Hmga2CK/CK mice 
developed pancreatic cancer with full penetrance and comparable histology (Fig. 2b,c). Thus, Hmga2-deficiency 
does not affect the histological phenotype of mouse pancreatic cancer.
To assess the effect of Hmga2-deficiency on cancer cell dissemination and metastasis, we quantified the devel-
opment of -metastases by fluorescence-stereomicroscopy. Distant metastases were present in the liver, peritoneal 
cavity, and lung in about 30–50% of mice. Hmga2-deficient and Hmga2-wildtype metastases in the KP172CT and 
KPHetCT models were histologically indistinguishable (Fig. 2a–c).
We also utilized the bright fluorescent marking conferred by the Rosa26tdTomato/+ allele to assess the presence 
of disseminated tumour cells (DTCs) in the peritoneal fluid and circulating tumour cells (CTCs) in the blood 
by flow cytometry for tdTomato+ cancer cells (Fig. 2d). DTCs were present in the peritoneal cavity of almost all 
KP172CT;Hmga2+/+ and KP172CT;Hmga2CK/CK mice and CTCs were present in five out of eight KP172CT;Hmga2+/+ 
and four out of eleven KP172CT;Hmga2CK/CK mice. The number of CTCs detectable in mice was variable, but was 
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not significantly different between KP172CT;Hmga2+/+ and KP172CT;Hmga2CK/CK mice (Fig. 2e and Supplemental 
Fig. S2). Collectively, these data suggest that Hmga2 is not required for dissemination and metastasis of pancre-
atic cancer.
Hmga2 deficiency does not alter PDAC sensitivity to gemcitabine. The nucleoside analogue gem-
citabine is one of the standard agents of care for PDAC patients12. In addition to its association with more advanced 
and metastatic human PDAC, HMGA2 has also been suggested to promote gemcitabine resistance of PDAC41,42. 
To investigate whether Hmga2 deficiency would increase PDAC sensitivity to gemcitabine in vivo, we assessed 
the impact of Hmga2 deficiency on overall survival with and without gemcitabine treatment. In the KrasLSL-G12D/+; 
p53flox/flox;Pdx1-Cre (KPKOC) model, pancreatic cancer develops rapidly and advanced disease is already pres-
ent 4 weeks after birth. KPKOC mice typically succumb to their very aggressive disease between 50 and 60 days 
of age43. To determine whether Hmga2 deficiency leads to increased sensitivity to gemcitabine, we generated 
KPKOC;Hmga2+/+ and KPKOC;Hmga2CK/CK mice (Fig. 3a). These mice were either treated with four intraperitoneal 
injections of gemcitabine (120 mg/kg) or vehicle control on days 28, 32, 35 and 39 of age (Fig. 3b). We moni-
tored overall survival as a metric of tumour response. Consistent with published reports, gemcitabine provided 
a small survival benefit to KPKOC;Hmga2+/+ mice (median survival of 61 days in control treated mice versus 77 
days in gemcitabine treated mice)24,44. However, the increase in survival was equally small in KPKOC;Hmga2CK/CK 
mice (16-day increase in survival in KPKOC;Hmga2+/+ mice treated with gemcitabine versus a 14-day increase 
in survival in KPKOC;Hmga2CK/CK mice treated with gemcitabine) and no significant difference in survival was 
detectable between gemcitabine treated KPKOC;Hmga2+/+ and gemcitabine treated KPKOC;Hmga2CK/CK mice 
Figure 1. Absence of Hmga2 does not alter overall survival in autochthonous mouse models of PDAC.  
(a) Alleles in the KP172CT (KrasLSL-G12D/+;p53LSL-R172H/+;R26LSL-Tom/+;Pdx1-Cre) and the KPHetCT (KrasLSL-G12D/+; 
p53flox/+;R26LSL-Tom/+;Pdx1-Cre) models before and after allele recombination. (b) Hmga2 expression in 
pancreatic tumors in KP172CT;Hmga2CK/+ mice overlaps with GFP in Tomato positive cancer cells. Hmga2 is 
absent in KP172CT;Hmga2CK/CK tumours. Representative of >10 tumors. Scale bars = 50 µm. (c,d) Kaplan-Meier 
survival curves of KP172CT (c) and KPHetCT (d) mice shows no significant difference with (Hmga2CK/CK) or 
without (Hmga2+/+) Hmga2 inactivation.
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(p = 0.515). This suggests that the absence of Hmga2 does not increase PDAC sensitivity to this standard chemo-
therapeutic agent. Furthermore, histological analysis of the tumours from gemcitabine treated KPKOC;Hmga2+/+ 
and KPKOC;Hmga2CK/CK mice uncovered comparable histology, with complete destruction of normal pancreatic 
architecture and development of undifferentiated and anaplastic PDAC (Fig. 3c,d). Thus, Hmga2 deficiency did 
not lead to gemcitabine sensitivity in vivo.
Hmga1 expression overlaps with Hmga2 expression, but Hmga1 does not compensate for 
Hmga2 deficiency. HMGA2 belongs to the family of HMGA proteins that consists of two family members, 
HMGA1 and HMGA226. Both proteins are considered architectural transcription factors that regulate transcrip-
tion indirectly by altering DNA conformation. In normal adult cells, both family members are almost unde-
tectable though they are abundant during embryonic development. Both family members have been shown to 
regulate cell signalling, proliferation, and differentiation with at least partially overlapping functions26,27,31,45. The 
expression of both HMGA1 and HMGA2 has been shown to correlate with advanced tumour stages and metasta-
sis in PDAC patients32. To investigate whether Hmga1 expression overlaps with Hmga2 expression, we performed 
immunohistochemistry and western blot analysis on murine and human PDAC tissue samples. In tumours from 
KP172CT;Hmga2CK/+ mice, Hmga1 and Hmga2 were expressed in primary tumour areas as well as in metastases 
in liver and lung (Supplemental Fig. 3a). In PDAC from KPHetCT;Hmga2+/+ mice the expression of Hmga1 and 
Hmga2 generally overlapped, with Hmga1 also being highly expressed in advanced primary tumours as well as 
in metastases (Fig. 4a). In PDAC from KPHetCT;Hmga2CK/CK mice, Hmga1 was still expressed at similar levels. 
Western blot analysis for Hmga1 and Hmga2 on sorted (lineagenegative, DAPInegative, Tomatopositive) cancer cells iso-
lated from pancreatic tumours from KPHetCT;Hmga2+/+ and KPHetCT;Hmga2CK/CK mice confirmed the absence of 
Hmga2, the presence of the GFP fusion protein in Hmga2-deficient tumours, and unaltered Hmga1 expression 
(Fig. 4b). Similarly, HMGA1 and HMGA2 proteins are often co-expressed in human PDAC (Fig. 4c). In TCGA 
PDAC dataset, HMGA1 and HMGA2 expression was also moderately correlated (0.414 Pearson correlation coef-
ficient or 0.581 Spearman correlation coefficient, respectively). Correlation of overall survival with HMGA1 
and HMGA2 protein expression showed that PDAC patients with tumours that were both HMGA1negative and 
Figure 2. Hmga2 deficiency does not alter the phenotype of pancreatic cancer in multiple autochthonous 
mouse models. (a,b) Representative histology of primary PDAC tumours and metastases from KP172CT (a) 
and KPHetCT (b) mice with (Hmga2+/+) or without (Hmga2CK/CK) Hmga2. Scale bars = 100 µm. (c) Incidence 
of primary PDAC and metastases in KP172CT and KPHetCT mice with (Hmga2+/+) or without (Hmga2CK/CK) 
Hmga2. All comparisons showed no significant differences. (d,e) Incidence of circulating tumour cells (CTC) 
and disseminated tumour cells (DTC) is comparable in KP172CT;Hmga2+/+ and KP172CT;Hmga2CK/CK mice (e) as 
detected by FACS (d) for tdTomatopos, lineageneg, DAPIneg cancer cells in blood (CTC) and pleural fluid (DTC). 
No significant differences in CTC number were observed.
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HMGA2negative had better overall survival than patients whose tumours expressed HMGA1 and/or HMGA2 
(Fig. 4d,e; p = 0.0022).
To test whether Hmga1 compensates for Hmga2 in PDAC metastasis, we generated PDAC cell lines from 
tumours from KP172CT;Hmga2+/+ and KP172CT;Hmga2CK/CK mice (n = 4 each). We performed qPCR analysis 
for Hmga1 and Hmga2 expression. Hmga1 expression was not affected by Hmga2-deficiency (Supplemental 
Fig. S3c,d). To investigate if Hmga1 could functionally compensate for Hmga2, we stably knocked down Hmga1 
in a cancer cell line generated from a KP172CT;Hmga2CK/CK lymph node metastasis. Knockdown at the RNA 
level was confirmed by qPCR (Fig. 4f). However, no significant difference in metastatic ability between control 
and Hmga1 knockdown cells was observed upon intravenous injection into immunocompetent recipient mice 
(Fig. 4g,h,i). Additionally, we stably knocked down Hmga1 or Hmga2 in a cell line generated from a liver metas-
tasis in a KP172CT;Hmga2+/+ mouse (Supplemental Fig. S4a). Intravenous transplantation of Hmga1 knockdown, 
Hmga2 knockdown, or control cells into immunocompetent recipient mice to seed metastases into the lungs 
showed no difference in the metastatic ability of control cells and cells deficient for either Hmga1 or Hmga2 
(Supplemental Fig. S4b).
Discussion
To investigate the function of the chromatin-associated protein Hmga2 during pancreatic cancer growth, 
metastasis, and treatment response, we took a classical genetic approach of specifically inactivating Hmga2 
protein expression in the well-established KP172CT, KPHetCT, and KPKOC mouse models of PDAC. To our sur-
prise, Hmga2-deficient tumours formed in the pancreata of KP172CT;Hmga2CK/CK, KPHetCT;Hmga2CK/CK, and 
KPKOC;Hmga2CK/CK mice with similar rate and morphology and within a comparable time course as in control 
KP172CT, KPHetCT and KPKOC mice (Fig. 2). By all metrics, from overall survival to histology of primary tumours 
and metastases to the presence and number of CTCs and DTCs, Hmga2-deficiency did not perturb PDAC devel-
opment in any significant way.
Numerous in vitro studies across several different human cancer types have suggested a role for HMGA2 
in controlling phenotypes associated with malignant transformation and metastasis32,36,42,46,47. However, very 
few studies have investigated Hmga2 function in autochthonous cancer models in vivo. In a mouse model of 
Wnt1-driven colorectal cancer, tumour formation was reduced in Hmga2−/− mice, suggesting a role for Hmga2 
in cancer development48. However, Hmga2−/− mice have severe dwarfism49, therefore the direct importance of 
Figure 3. Hmga2 deficiency does not dramatically alter PDAC sensitivity to gemcitabine. (a–c) 
KPKOC;Hmga2+/+ and KPKOC;Hmga2CK/CK mice (a) were treated with four intraperitoneal gemcitabine 
injections at 28, 32, 35, and 39 days of age (b) and compared to their respective vehicle-treated control 
littermates. Gemcitabine treatment slightly increased median survival in both genotypes (65.5 days in 
KPKOC;Hmga2CK/CK and 77 days in KPKOC;Hmga2+/+ mice) compared to untreated controls (51.5 days in 
KPKOC;Hmga2CK/CK and 61 days in KPKOC;Hmga2+/+ mice), but no significant survival difference was observed 
between gemcitabine -treated KPKOC;Hmga2CK/CK and KPKOC;Hmga2+/+ mice (p = 0.47) (c). (d) Representative 
histology of tumours in KPKOC;Hmga2+/+ and KPKOC;Hmga2CK/CK mice treated with gemcitabine. Across all 
mice, no consistent changes in histology were observed. Scale bars = 50 µm.
www.nature.com/scientificreports/
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Hmga2 in colorectal cancer cells in vivo remains unclear. Furthermore, in squamous skin cancer mouse models, 
Hmga2 was found to be dispensable for tumour initiation and progression50. While we recently showed that 
Hmga2 is a marker of a transient metastatic subpopulation in PDAC in vivo13, our current study shows that nei-
ther deletion of Hmga2 in autochthonous mouse models of PDAC, nor knockdown of Hmga2 in an aggressive 
Figure 4. Hmga1 and Hmga2 are co-expressed in mouse and human pancreatic cancer. (a) Immunohistochemistry 
for Hmga1 and Hmga2 in wild type (WT), KrasLSL-G12D/+;Pdx1-Cre (KC) and KrasLSL-G12D/+;p53flox/+;R26LSL-Tom/+; 
Pdx1-Cre (KPHetCT) mice shows co-expression of Hmga1 and Hmga2 in PDAC and metastases but not in 
preneoplastic lesions or healthy pancreata. Scale bars = 50 µm. (b) Western Blot on sorted cancer cells from 
KPHetCT;Hmga2+/+ and KPHetCT;Hmga2CK/CK mice documents the expression of the GFP-fusion reporter 
gene and the absence of Hmga2 in cells from KPHetCT;Hmga2CK/CK mice. Hmga1 expression is not affected. 
Corresponding full length images and details regarding probing of the membranes are available in Supplemental 
Fig. S4c. (c) Tissue microarrays from human pancreatic cancer patients were stained for HMGA1 and HMGA2. 
Scale bars = 50 µm. (d) Kaplan-Meier survival analysis for patients with HMGA1 and HMGA2 positive or 
negative tumours. (e) Median survival in months of PDAC patients with expression of HMGA1 and HMGA2 
shows that patients with HMGA1negative/HMGA2negative tumours have significantly (p = 0.0022) better overall 
survival than patients who have tumors that express of either HMGA1 or HMGA2 or both. (f–i) Knockdown 
of Hmga1 in a cell line (2648LN) isolated from a lymph node metastasis from a KP172CT;Hmga2CK/CK mouse has 
no significant impact on their metastatic potential upon intravenous injection into recipient mice. (f) qPCR 
was used to assess knockdown; mean +/− SEM of triplicate wells is shown. (g) Representative brightfield 
and fluorescent images of one lung lobe and corresponding histology. Scale bars in the upper and middle 
panels = 4 mm; scale bars in the lower panels = 50 µm. (h,i) Quantification of %-Tomatopositive area (h) and 
number of tdTomatopositive tumours in the lung (i), n = 3 mice per group; the red line indicates the mean.
www.nature.com/scientificreports/
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pancreatic cancer cell line impacted pancreatic tumour initiation, progression, or metastatic ability. In the genet-
ically engineered mouse models that we used, Hmga2 deletion occurs concomitantly with expression of KrasG12D 
and inactivation of p53 during tumour initiation, and therefore tumours develop in the complete absence of 
Hmga2. This could lead to an alternative, Hmga2-independent mechanism for PDAC growth and progression. 
Second hit mouse models of PDAC could provide additional information on whether acute Hmga2 inactivation 
in PDAC impacts growth, progression, or therapy response.
In contrast to human non-small cell lung cancer cell lines35, cell lines derived from the KrasG12D-driven 
p53-deficient mouse lung adenocarcinoma model38, and the mouse breast cancer cell line 4T148, Hmga2 knock-
down in murine PDAC cells did not reduce metastatic ability in vivo. This is particularly interesting as PDAC is 
among the most genetically stable cancer entities and its progression is based on epigenetic changes rather than 
acquisition of additional DNA mutations11,14, suggesting an even greater importance of epigenetic reprogram-
ming of malignant cells39,51.
HMGA2 has been previously implicated in resistance to gemcitabine in human pancreatic cancer cell lines 
in vitro, where HMGA2 knockdown sensitized PDAC cells to gemcitabine treatment42. HMGA2 mediated gem-
citabine resistance in three-dimensional collagen cultures of PDAC cell lines via increased histone acetylation41. 
To test whether Hmga2 mediates gemcitabine resistance in vivo, we utilized a well-established clinically relevant 
treatment model44,52,53. Neither overall survival nor histology of the tumours in mice treated with gemcitabine 
were significantly affected by Hmga2-deficiency. While these models have limited resolution to detect modest 
effects, our results suggest that Hmga2 has limited if any effect on gemcitabine resistance in vivo. Despite Hmga2 
having no effect in gemcitabine-treated mouse models of pancreatic cancer, it remains possible that HMGA2 may 
still be a determinant of therapy sensitivity in human PDAC or of response to other chemotherapies.
We also investigated whether HMGA1, a HMGA2 family member with related functions, compensates for 
HMGA2 during PDAC metastasis. We and others have shown that HMGA1 and HMGA2 overlap in their expres-
sion in human PDAC and in KP172CT and KPHetCT mice (Fig. 4, ref.32). Additionally, the expression of HMGA1 
and HMGA2 correlates with poor survival of PDAC patients32. Notably, PDAC patients with HMGA1negative 
HMGA2negative tumours have significantly better survival than all other patients (Fig. 4d). Cancer cells from 
KPHetCT;Hmga2+/+ and KPHetCT;Hmga2CK/CK mice express Hmga1 at similar levels, therefore Hmga1 could com-
pensate for Hmga2 deficiency to enable malignant transformation and metastasis. Knockdown of Hmga1 in a PDAC 
cancer cell line generated from a KP172CT;Hmga2CK/CK mouse had no impact on metastatic ability after intravenous 
transplantation. Hmga1 knockdown in our system might not have been sufficient to entirely remove Hmga1 func-
tion, with remaining Hmga1 levels still being adequate to enable metastasis. Alternatively, a pro-metastatic effect of 
Hmga1/Hmga2 could be stable and not depend on continued Hmga1 expression. In vivo models that incorporate 
genetic deletion of both Hmga1 and Hmga2 will allow this question to be addressed definitively.
Taken together, we provide evidence that Hmga2 is functionally dispensable for the malignant transforma-
tion, progression, and metastatic ability of pancreatic cancer in vivo. Our results support Hmga2 being solely of 
prognostic value, as has been shown for multiple cancer types29–31,34. Hmga2 remains a prognostic marker which 
identifies an advanced cancer cell state in primary pancreatic tumours and marks a metastasis-driving subpopu-
lation of cancer cells.
Methods
Mice. KrasLSL-G12D, p53LSL-R172H, p53flox, Pdx1-Cre, Rosa26LSL-tdTomato, and Hmga2CK mice have been described40,54–58. 
For gemcitabine treatment, 28 day old KrasLSL-G12D/+;p53flox/flox;R26LSL-Tom/+;Pdx1-Cre and KrasLSL-G12D/+; 
p53flox/flox;Hmga2CK/CK;R26LSL-Tom/+;Pdx1-Cre were randomly separated into two groups each (mixed gender) and 
treated with four intraperitoneal injections of gemcitabine (120 mg/kg) or saline on day 28, 32, 35, and 39 of age. 
For transplantation of knockdown cell lines, 2 × 104 cells were injected into the lateral tail vein of male 129/Bl6 
F1 mice (Jackson Laboratories, Stock number 101043). Mice were analysed 3 weeks after injection. No statisti-
cal method was used to predetermine sample size. All experimental protocols were approved by the Stanford 
University Animal Care and Use Committee and performed in accordance with their guidelines.
Histology and immunohistochemistry on mouse PDAC. Tissues were fixed in 4% formalin in PBS 
overnight and transferred to 70% ethanol prior to paraffin embedding. After de-parafinization, re-hydration, 
and antigen retrieval, IHC was performed on 4 μm sections with the ABC Vectastain kit (PK-4001, Vector 
Laboratories Inc.) with antibodies to Hmga2 (59170AP, BioCheck Inc.), Tomato (600-401-379, Rockland Inc.), 
GFP (ab6673, Abcam), CK19 (TROMA-III, Developmental Studies Hybridoma Bank), Insulin (A0564, Dako) 
and Hmga1 (sc-8982, Santa Cruz). Sections were developed with DAB and counterstained with haematoxylin. 
Haematoxylin and Eosin (H&E) staining was performed using standard methods.
Tumour dissociation and cancer cell flow cytometric analysis. Pancreatic tumours and metas-
tasis were dissociated into a single cell suspension prior to FACS analysis. Briefly, tumours were minced with 
sharp scissors and incubated for 20 minutes at 37oC in HBSS medium (Corning, 21-022-CV) with collagenase 
IV (Worthington, 1 mg/ml, LS004188) and dispase (Corning, 354235) followed by quenching with ice-cold 
L-15 medium (Invitrogen, 21083-027) containing 10% FBS and DNase (20 μg/mL). Cells were stained with 
Allophycocyanin (APC)-conjugated antibodies to CD45 (30-F11), CD31 (390), F4/80 (BM8), and Ter119 (TER-
119, all from BioLegend) to exclude hematopoietic and endothelial cells. DAPI was used to exclude dead cells. 
Cells within the peritoneal cavity were collected immediately after euthanasia by making a small incision in 
the peritoneum followed by introduction of 1 ml PBS. For circulating tumour cell analysis blood was collected 
immediately after euthanasia by cardiac puncture. Red blood cell lysis was performed by incubation with ACK 
lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA). BD LSR II analysers and FACSAria sorters (BD 
Biosciences) were used and FlowJo software was utilized for analysis.
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Immunohistochemistry for HMGA1 and HMGA2 on human PDAC. Expression of HMGA1 and 
HMGA2 was assessed using IHC on 4 μm sections of paraffin-embedded tissue from each TMA. Sections were 
heated at 60 °C for 60 minutes, de-paraffinized in xylene and rehydrated through a graded alcohol series. Three 
percent H2O2 block was used to quench endogenous peroxidase activity. Antigen retrieval was performed in a 
de-cloaking chamber using a Borg Decloaker RTU antigen retrieval solution (Biocare Medical). Sections were 
then blocked in normal horse serum (Vector Laboratories) and incubated in a humidified chamber overnight 
at 4 °C with a 1:1000 dilution of primary anti-HMGA1 antibody (sc-8982, Santa Cruz) or anti-HMGA2 anti-
body (59170AP, BioCheck). Slides were washed in PBS and incubated with biotinylated anti-rabbit secondary 
antibody (Vector Laboratories) for 30 minutes at room temperature. Staining was visualized using DAB (Vector 
Laboratories) at room temperature. Slides were then counterstained with haematoxylin, rinsed in water and 
dehydrated through a graded alcohol series and xylene, and mounted with VectaMount (Vector Laboratories). 
HMGA1 and HMGA2 staining of individual samples was evaluated manually and an arbitrary cutoff of staining 
intensity was used to determine if a sample was considered negative or positive. Overall survival (OS) was defined 
as the time of surgery to the date of death from any cause. OS was analysed using Kaplan–Meier and log-rank 
tests. Significance was determined as a p-value < 0.05.
This study was approved by the Stanford University Institutional Review Board and performed in accordance 
with their guidelines, with a waiver of informed consent to use patient tissue and specimens.
Generation and selection of murine PDAC cell lines. We generated polyclonal cell lines from pri-
mary tumours and metastases that formed in the autochthonous KrasLSL-G12D/+;Trp53LSL-R172H/+;RosaLSL-tdTomato; 
Pdx1-Cre pancreatic cancer mouse model with (Hmga2+/+) and without (Hmga2CK/CK) Hmga2 expression22,54. To 
establish the cell lines, a piece of the tumour or macro-metastasis was dissociated into a single cell suspension, 
washed twice with cold PBS, minced with a scalpel and transferred to a tissue culture dish containing DMEM 
media (high glucose with 10% FBS and antibiotics). Cells were allowed to attach and grown for one week with 
two media changes. Then cells were passaged at least 3 times to select away from fibroblast contamination. Purity 
was confirmed by FACS for tdTomato and MycoAlert Mycoplasma detection kit (Lonza) was used to verify the 
lack of Mycoplasma contamination.
Lentiviral knockdown and qRT-PCR analysis. Hmga1 and Hmga2 were knocked down using pLKO 
lentiviral vectors; mouse shHmga11 (TRCN0000182651) and mouse shHmga2 (TRCN0000126044). The con-
trol vector was pLKO-shLuciferase. Virus production, cell infection, and selection were performed as previ-
ously described59. Knockdown was confirmed by qPCR and western blotting. qRT-PCR for mouse Hmga1 
(Hmga1_Fw GGGGCAGACCCAAGAAAC and Hmga1_Rv GGCACTGCGAGTGGTGAT) and Hmga2 
(Hmga2_Fw GGATCCTGGCAGAAACTTCC and Hmga2_Rv AACGGGACAGAGATAGAGACTGA) 
was performed using standard SYBR green qPCR protocols and normalized to mouse Gapdh (Gapdh_Fw 
TTTGATGTTAGTGGGGTCTCG and Gapdh-Rv AGCTTGTCATCAACGGGAAG).
Western blot analyses. Cells were pelleted before lysis with standard RIPA buffer supplemented with 1/100 
volume of protease inhibitor cocktail (Sigma-Aldrich, P8340). Lysates were denatured in Laemmli buffer with 
β-mercaptoethanol before loading onto a precast 4–12% Bis-Tris PAGE gel (Invitrogen, NP0321BOX). Separated 
samples were then transferred onto a PVDF membrane (Bio-Rad, 162-0177) before staining with the follow-
ing antibodies overnight: anti-Hmga2 (Biocheck, 59170AP, or Thermo Scientific, P52926), anti-Hsp90 (BD 
Biosciences, 610418), and anti-Hmga1 (Santa Cruz, sc-8982 or sc-393213). For the secondary antibodies, goat 
anti-rabbit IgG-HRP (Santa Cruz Biotech, sc-2004), goat anti-mouse IgG-HRP (Santa Cruz Biotech, sc-2005), 
and donkey anti-goat IgG-HRP (Santa Cruz Biotech, sc-2020) were used. For enhanced chemiluminescence, 
Thermo Scientific Pierce ECL 2 Western Blotting Substrate (PI80196) was used.
Statistical analysis. Graphs and statistics were generated using GraphPad Prism software. Significance, 
where indicated, was calculated using the Wilcoxon test for non-normally distributed data. Survival was com-
pared using Kaplan–Meier plots and log-rank tests. Significance was determined as a p-value < 0.05. No statistical 
method was used to predetermine sample size.
Data Availability
No datasets were generated during the current study.
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